BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36759726)

  • 21. The expression profiles of signature genes from CD103
    Xia ZA; Lu C; Pan C; Li J; Li J; Mao Y; Sun L; He J
    BMC Med; 2023 Jul; 21(1):268. PubMed ID: 37488535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intratumoral CD103
    Gu Y; Chen Y; Jin K; Cao Y; Liu X; Lv K; He X; Lin C; Liu H; Li H; He H; Qin J; Li R; Zhang H; Zhang W
    Oncoimmunology; 2020 Nov; 9(1):1844402. PubMed ID: 33312758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intratumoral TIGIT
    Liu Z; Zhou Q; Wang Z; Zhang H; Zeng H; Huang Q; Chen Y; Jiang W; Lin Z; Qu Y; Xiong Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang J; Chang Y; Zhang W
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy.
    Komdeur FL; Wouters MC; Workel HH; Tijans AM; Terwindt AL; Brunekreeft KL; Plat A; Klip HG; Eggink FA; Leffers N; Helfrich W; Samplonius DF; Bremer E; Wisman GB; Daemen T; Duiker EW; Hollema H; Nijman HW; de Bruyn M
    Oncotarget; 2016 Nov; 7(46):75130-75144. PubMed ID: 27650547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma.
    Lohneis P; Sinn M; Bischoff S; Jühling A; Pelzer U; Wislocka L; Bahra M; Sinn BV; Denkert C; Oettle H; Bläker H; Riess H; Jöhrens K; Striefler JK
    Eur J Cancer; 2017 Sep; 83():290-301. PubMed ID: 28772128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic values of tissue-resident CD8
    Chen L; Huang H; Huang Z; Chen J; Liu Y; Wu Y; Li A; Ge J; Fang Z; Xu B; Zheng X; Wu C
    World J Surg Oncol; 2023 Apr; 21(1):124. PubMed ID: 37024870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prognostic value of tumor infiltration immune cells in pancreatic cancer].
    Zhao KL; Liu J; Jiang WN; Hao JH
    Zhonghua Wai Ke Za Zhi; 2018 Jun; 56(6):464-470. PubMed ID: 29886672
    [No Abstract]   [Full Text] [Related]  

  • 28. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients.
    Djenidi F; Adam J; Goubar A; Durgeau A; Meurice G; de Montpréville V; Validire P; Besse B; Mami-Chouaib F
    J Immunol; 2015 Apr; 194(7):3475-86. PubMed ID: 25725111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implication of CD69
    Kim HD; Jeong S; Park S; Lee YJ; Ju YS; Kim D; Song GW; Lee JH; Kim SY; Shin J; Shin EC; Hwang S; Yoo C; Park SH
    Liver Int; 2021 Apr; 41(4):764-776. PubMed ID: 33548061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer.
    Bösmüller HC; Wagner P; Peper JK; Schuster H; Pham DL; Greif K; Beschorner C; Rammensee HG; Stevanović S; Fend F; Staebler A
    Int J Gynecol Cancer; 2016 May; 26(4):671-9. PubMed ID: 26905331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade.
    Banchereau R; Chitre AS; Scherl A; Wu TD; Patil NS; de Almeida P; Kadel Iii EE; Madireddi S; Au-Yeung A; Takahashi C; Chen YJ; Modrusan Z; McBride J; Nersesian R; El-Gabry EA; Robida MD; Hung JC; Kowanetz M; Zou W; McCleland M; Caplazi P; Eshgi ST; Koeppen H; Hegde PS; Mellman I; Mathews WR; Powles T; Mariathasan S; Grogan J; O'Gorman WE
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33827905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer.
    Laumont CM; Wouters MCA; Smazynski J; Gierc NS; Chavez EA; Chong LC; Thornton S; Milne K; Webb JR; Steidl C; Nelson BH
    Clin Cancer Res; 2021 Jul; 27(14):4089-4100. PubMed ID: 33963000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD103
    Wang P; Huang B; Gao Y; Yang J; Liang Z; Zhang N; Fu X; Li L
    Cell Immunol; 2018 Mar; 325():48-55. PubMed ID: 29448979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.
    Massi D; Romano E; Rulli E; Merelli B; Nassini R; De Logu F; Bieche I; Baroni G; Cattaneo L; Xue G; Mandalà M
    Eur J Cancer; 2017 Jun; 78():70-81. PubMed ID: 28412591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effector T lymphocyte subsets in human pancreatic cancer: detection of CD8+CD18+ cells and CD8+CD103+ cells by multi-epitope imaging.
    Ademmer K; Ebert M; Müller-Ostermeyer F; Friess H; Büchler MW; Schubert W; Malfertheiner P
    Clin Exp Immunol; 1998 Apr; 112(1):21-6. PubMed ID: 9566785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors.
    Andersen LB; Nørgaard M; Rasmussen M; Fredsøe J; Borre M; Ulhøi BP; Sørensen KD
    J Pathol; 2021 Oct; 255(2):155-165. PubMed ID: 34255349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-1 Expression Defines Epidermal CD8
    Phadungsaksawasdi P; Fujiyama T; Kurihara K; Ito T; Honda T; Tokura Y
    J Invest Dermatol; 2021 Oct; 141(10):2426-2435.e5. PubMed ID: 33845077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune profiling identifies CD8
    Chen Z; Guo ML; Li YY; Yan K; Li L; Shen F; Guan H; Liu QZ; Xu B; Lian ZX
    Front Immunol; 2022; 13():894919. PubMed ID: 36420264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Downregulation of SEPTIN5 inhibits prostate cancer progression by increasing CD8
    Chang M; He Y; Liu C; Lin R; Huang X; Liang D; Zhang J; Lu Y
    Int J Biol Sci; 2022; 18(16):6035-6051. PubMed ID: 36439885
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.